Am J Transplant, Volume 5, Suppl 3 Archives - Page 52 of 170 - ATC Abstracts

2015 American Transplant Congress
Biomarker Panel Profile for Identification of High-Risk Patients After Heart Transplantation
M. Barten,¹ M.-T. Dieterlen,² J. Garbade,² F. Mohr.²
¹Cardiovascular Surgery, Universisty Heart Center Hamburg, Hamburg, Germany; ²Cardiac Surgery, University Leipzig Heart Center, Leipzig, Germany.
Background: The first year after cardiac transplantation is critical for transplant survival and long-term outcome. Identification of suitable biomarkers for detection of rejection processes is…
2015 American Transplant Congress
The Effect of Systemic Catecholamine Application On the Microcirculation in Liver Procurement
M. Strempel,¹ M. Kaths,¹ H. Lang,¹ G. Otto,¹ V. Weyer,² O. Kempski,³ A. Heimann,³ A. Schad,⁴ D. Foltys.¹
¹Department of Transplantation and Hepatobiliopancreatic Surgery, University Medical Centre, Johannes Gutenberg-University, Mainz, Germany; ²Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre, Johannes Gutenberg-University, Mainz, Germany; ³Institute of Neurosurgical Pathophysiology, University Medical Centre, Johannes Gutenberg-University, Mainz, Germany; ⁴Institute of Pathology, University Medical Centre, Johannes Gutenberg-University, Mainz, Germany.
Introduction: The most vulnerable part in liver transplantation remains the biliary system. There is evidence, that insufficient perfusion during multi-organ procurement plays a major role…
2015 American Transplant Congress
The Immunosuppressive Effect of CTLA4Ig Monotherapy Depends On the Presence of Tregs Only at Suboptimally Low Doses
C. Schwarz,¹ L. Unger,¹ B. Mahr,¹ K. Aumayr,² N. Pilat,¹ K. Hock,¹ A. Farkas,¹ I. Kristo,¹ T. Wekerle.¹
¹Dept. of Surgery, Medical University of Vienna, Vienna, Austria; ²Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.
Background: CTLA4Ig/belatacept has been recently approved for immunosuppression after renal transplantation. Concerns persist, however, that a paradoxical dose-response relationship might exist for CTLA4Ig in which…
2015 American Transplant Congress
Mechanisms Underlying Treg Dysfunction in DAIH- Role for PD-L1?
A. Arterbery,¹ M. Martinez,² S. Lobritto,² Y. Avitzur,³ K. Raddassi,¹ M. Kleinewietfeld,⁴ U. Ekong.¹
¹Yale, NH; ²Columbia, NY; ³HSC, Toronto, Canada; ⁴Dresden University of Technology, Dresden, Germany.
Background: we have previously shown that ex vivo Tregs from patients with DAIH demonstrate differentiation plasticity towards TH17. To understand the mechanisms underlying this we…
2015 American Transplant Congress
No Tumor Recurrence After Renal Cell Carcinoma Resected Kidney Transplantation – 5 Year Follow Up
M. Zwierzchoniewska,¹ K. Fong,¹ D. Patel,¹ L. Mou, W. Lim,² B. He,¹ L. Delriviere.¹
¹Western Australian Kidney Transplant Surgery Service, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; ²Western Australian Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
INTRODUCTION:Organ shortage remains the single most significant impediment to increasing low rate of kidney transplantation. One of the strategies to improve it, is a utilisation…
2015 American Transplant Congress
Calcineurin (CNI) Exposure Reduces the Risk of Post-Transplant DSA After Deceased Donor Kidney Transplantation
R. Pelletier, A. Rajab, G. Bumgardner, M. Henry.
General Surgery, The Ohio State University, Columbus, OH.
We use ATG induction with immediate rapamune (Rapa) and delayed CNI immunosuppression following kidney transplantation. Mycophenolic acid (MPA) is substituted for CNI to avoid renal…
2015 American Transplant Congress
Interleukin-17 Deficiency Attenuates Renal Allograft Injury and Prolongs Survival in a Murine Transplantation Model
T. Kwan,^1,2 S. Chadban,^1,2 J. Ma,^1,2 S. Bao,^2,3 S. Alexander,^2,4 H. Wu.^1,2
¹Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; ²Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; ³Discipline of Pathology, School of Medical Sciences, Sydney, New South Wales, Australia; ⁴Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Aim:To investigate the role of IL-17 in allograft rejection using a murine model of fully MHC-mismatched renal transplantation.Methods:Life-sustaining kidney transplants were performed in nephrectomized mice:…
2015 American Transplant Congress
The Effects of Periostin on Renal Fibrosis After Ischemia-Reperfusion Injury Via p38 MAPK Pathway
J. An,^1,2 S. Yang,³ J. Hwang,⁴ J. Kim,¹ S. Kim,^2,5 C. Lim,^1,2 Y. Oh,^1,2 Y. Kim,² J. Lee.^1,2
¹Seoul National University Boramae Medical Center, Seoul, Republic of Korea; ²Seoul National University Hospital, Seoul, Republic of Korea; ³Seoul National University Kidney Research Institute, Seoul, Republic of Korea; ⁴Chung-Ang University Hospital, Seoul, Republic of Korea; ⁵Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Ischemia-reperfusion injury during the transplantation procedure is associated with poor long-term allograft outcomes, such as rejection and fibrosis. Periostin, a matricellular protein, has been reported…
2015 American Transplant Congress
Type III Phosphodiesterase (PDE3) Inhibitor Improves Survival Rate After Ischemia Reperfusion Injury of the Liver in Rats
T. Fujii,¹ H. Obara,² N. Fujimura,² K. Matsubara,² Y. Kitagawa.²
¹Surgery, Inagi Municipal Hospital, Tokyo, Japan; ²Surgery, Keio University School of Medicine, Tokyo, Japan.
BackgroundPDE3 inhibitor (Cilostazol) has long been used as a potent inhibitor of platelet aggregation and thrombosis. Recently, there have been a report on the protective…
2015 American Transplant Congress
Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations
T. Elnahhas,^1,2 T. Lee,² M. Moreton,² D. McKeown,² J. Popoola,³ R. Ramkhelawon,³ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology Department, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St.George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St.George's University of London, London, United Kingdom.
Background. Tacrolimus is available in two formulations, immediate-release, (Prograf®) and prolonged -release formulation of tacrolimus (Advagraf®). Tacrolimus has a narrow therapeutic index with wide variation…